Si, estaría bien , entre hoy y mañana confirmara, daría cruce en es stocastico y en el MACDi que suba por encima de 0, a ver cómo acaba la semana, y si es así la vela semanal también quedaría niquelada...
#125341
Re: Farmas USA
Me encanta esta página, todo a la vista .... moooola
SDGR presenta resultados Q3, buenos, 3,9$ net income, entramos en "profitabilidad" https://newsfilter.io/a/93191aefb26cf1d3ddf9b404d5a483c0 PLTR presenta hoy primeros resultados desde que cotiza, la gente entrando bastante en el pre, casi 500k acciones a 16,5$ aprox, las llevo a 10$ no esperaba una subida tan rápida al contrario pensaba que bajaria y podría ir completando posición, veremos
SDGR Total revenue of $25.8 million, up 29% year-over-year;
Software revenue of $22.9 million, up 42% year-over-year
Raised $325.6 million net proceeds in equity financing
Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition
Conference call today, Thursday, Nov. 12, 2020 at 8:30 a.m. ET
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results for the third quarter ended September 30, 2020.
"We are executing on our strategic plan across every area of our business," said Schrödinger CEO Ramy Farid, Ph.D. "We’re excited about the strong growth we’ve seen in our software business and the rapid progress of our internal and collaborative programs to discover and develop therapeutics."
Third Quarter Financial Results
Revenue was $25.8 million for the third quarter of 2020, an increase of 29% compared to the third quarter of 2019.
Software revenue was $22.9 million for the third quarter of 2020, an increase of 42% over the third quarter in 2019. Drug discovery revenue was $2.9 million for the third quarter of 2020, a decline of 24% versus the third quarter of 2019.
Gross profit reached $15.3 million in the third quarter of 2020, an increase of 43% over the third quarter in 2019. Software gross margin was 81% in the third quarter, unchanged versus the third quarter of 2019.
Operating expenses for the third quarter of 2020 were $30.7 million, an increase of 40% over the third quarter of 2019.
Other income, which includes gains on equity investments and changes in fair value of such investments, was $18.7 million in the third quarter of 2020 versus a loss of $0.9 million in the third quarter of 2019. Other income for the third quarter of 2020 included an $18.0 million non-cash gain from our equity in Relay Therapeutics which completed its IPO in July 2020.
Net income, after adjusting for non-controlling interests, was $3.9 million for the third quarter of 2020, compared to a net loss of $11.5 million in the third quarter of 2019.
Schrödinger ended the third quarter of 2020 with cash, cash equivalents, restricted cash and marketable securities of $599.5 million, an increase of $315.0 million from the end of the second quarter of 2020, primarily as a result of net proceeds of $325.6 million from the equity financing in the third quarter.
"In the third quarter, we continued the excellent momentum across our business established in the first half of 2020," said Schrödinger CFO Joel Lebowitz. "With our strong balance sheet and growing revenue, we believe we are well-positioned to continue to invest in R&D and execute on all elements of our strategy."
Third Quarter Business Update
Driving growth in our Software business
42% revenue growth in the third quarter of 2020, driven by growth in both Life Sciences and Materials Science revenue
Increased Financial resources
Raised $325.6 million of net proceeds from an equity follow-on offering
Ending cash, cash equivalents, restricted cash and marketable securities for the third quarter were $599.5 million
Advancing internal discovery programs and pipeline progress
Expect to initiate IND enabling studies in 2021 on most advanced internal programs
Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition; progressing research in single agent and combination studies targeting B-cell lymphomas
Advancing the underlying science of our platform and methods
Several scientific publications describing and validating our differentiated computational platform
Improved methods for accurately modeling the relative binding free energies of metalloenzyme inhibitors
Improved approaches to optimize binding selectivity
Validation and extension of our technologies to more comprehensively support macrocycle design and optimization
"We are very pleased with the significant progress we have made this year on our software business, our drug discovery collaborations and our internal pipeline," said Dr. Farid. "Our ongoing commitment to advance the science underlying our industry-leading physics-based computational platform to achieve new breakthroughs will drive our continued success."
